SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative ...
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell ...
SANTA FE, N.M., Oct. 1, 2025 /PRNewswire/ -- Mercury Bio (www.mercurybio.com), a drug delivery company leveraging its novel and proprietary extracellular vesicle (EV) drug encapsulation platform (yEV™ ...
Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments To accelerate partnering efforts with global pharmaceutical ...
A bio-inspired adhesive patch puts some mussel into treating glioblastoma – the most aggressive brain tumor.
Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I analyze the recently announced ...
JuneBrain Inc., a Baltimore-based neurotech startup, took first place at the 2025 BioChallenge Pitch Competition, held October 30 at the New Orleans BioInnovation Center (NOBIC). The annual contest ...
Glioblastoma is the most common and aggressive malignant brain tumor in adults. Although microtubule-targeting agents (MTAs) are among the most widely used first-line therapies in cancer, their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results